CSIMarket
 
Myovant Sciences Ltd   (MYOV)
Other Ticker:  
 
 
Price: $26.9800 $-0.01 -0.037%
Day's High: $27 Week Perf: 0.11 %
Day's Low: $ 26.98 30 Day Perf: 0.26 %
Volume (M): 2,256 52 Wk High: $ 0.00
Volume (M$): $ 60,867 52 Wk Avg: $0.00
Open: $26.99 52 Wk Low: $0.00



 Market Capitalization (Millions $) 2,613
 Shares Outstanding (Millions) 97
 Employees 450
 Revenues (TTM) (Millions $) 379
 Net Income (TTM) (Millions $) -184
 Cash Flow (TTM) (Millions $) -211
 Capital Exp. (TTM) (Millions $) 1

Myovant Sciences Ltd
Myovant Sciences Ltd. is a United Kingdom-based pharmaceutical and healthcare company dedicated to developing and commercializing innovative medicines to improve the lives of women and men around the world. They focus on reproductive medicine, urology, and endocrinology, particularly on developing therapeutics which focus on hormonal conditions.

The company was founded in 2016 by Takeda Pharmaceutical Co. Ltd. and Roivant Sciences Ltd in order to combine Takeda's global resources and strategic focus on oncology with Roivant's expertise in a broad array of therapeutic areas. Since Roivant had a strong track record of bringing new drugs to market, Myovant Sciences was established to focus on developing and commercializing innovative medicines to address unmet needs in women's health and prostate cancer.

Their lead product candidate, Relugolix, is a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist, which was developed to address unmet medical needs in women and men with hormone-related diseases. Relugolix is currently under review by regulatory authorities in the United States, Europe and Japan for the treatment of uterine fibroids, endometriosis, and advanced prostate cancer.

Myovant Sciences is also focused on developing and commercializing other innovative treatments for women's health conditions, such as menorrhagia, polycystic ovary syndrome (PCOS), and breast cancer. Their product portfolio includes several potential therapies in various stages of development, such as MVT-602, a kisspeptin agonist for controlled ovarian hyperstimulation in patients undergoing in vitro fertilization, and MVT-605, an oral selective estrogen receptor degrader (SERD) for the treatment of advanced breast cancer.

Through a series of partnerships and collaborations, Myovant Sciences has established a strong global presence, with operations in the United States, Japan, and Switzerland, and a network of partners across Europe and Asia. Their collaborations include an ongoing partnership with Pfizer to develop a drug for the treatment of uterine fibroids, a co-development and commercialization agreement with Sumitomo Dainippon Pharma for relugolix in Japan, and a strategic partnership with AbbVie for up to $4 billion to develop and commercialize relugolix in other indications such as endometriosis and uterine fibroids.

In addition to developing innovative medicines, Myovant Sciences is committed to positively impacting the communities it serves. They have established programs such as the Inspire Scholarship, which provides financial assistance to women pursuing graduate education in science, technology, engineering or math (STEM) fields, and partnerships with organizations such as the Black Women's Health Initiative and the National Organization for Rare Disorders (NORD) to create greater awareness of rare diseases and support patient advocacy efforts.

Overall, Myovant Sciences is a well-established pharmaceutical company that is focused on developing innovative treatments for hormone-related diseases in women and men, and is committed to delivering value to its stakeholders through partnerships, collaborations, and socially responsible initiatives.


   Company Address: 50 Broadway London 0
   Company Phone Number: 400 3351   Stock Exchange / Ticker: NYSE MYOV
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Neurogene Inc

Neurogene Inc. Breaks Ground in Rare Neurological Disorder Research with Expansion of NGN-401 Trial

Neurogene Inc., a leading clinical-stage company specializing in genetic medicines for rare neurological disorders, has recently announced its plans to expand its Phase 1/2 gene therapy clinical trial for NGN-401. This trial is particularly focused on female pediatric patients suffering from Rett syndrome, a debilitating genetic disorder that primarily affects the nervous system. In addition to expanding the trial, Neurogene Inc. also aims to improve the enrollment process to allow for faster participation and assessment.
Rett syndrome, although considered a rare condition, has a profound impact on the lives of patients and their families. It predominantly affects females and is caused by mutations in the MECP2 gene. Symptoms typically appear between six to eighteen months after birth and result in severe impairments in physical, cognitive, and social functioning. Children with Rett syndrome often lose purposeful hand skills, experience regression in language and motor abilities, exhibit repetitive hand movements, and develop respiratory irregularities. Currently, there is no cure for Rett syndrome, and treatment primarily focuses on managing symptoms and providing supportive care.

Eyenovia Inc

Eyenovia Inc Faces Challenges as Shares Plummet and Future Prospects Remain Uncertain



Eyenovia Inc, a major pharmaceutical preparations company, has witnessed a significant drop in its shares over the past month. This decline adds to the year-to-date poor performance. Additionally, the company is currently trading on the NASDAQ well below its 52-week average. These developments raise concerns about Eyenovia's future prospects and its ability to overcome these challenges. Furthermore, factors such as a co-promotion agreement and recent financial results also contribute to the uncertainty surrounding the company's future.
1. Co-Promotion Agreement with NovaBay Pharmaceuticals:
Eyenovia's strategic partnership with NovaBay Pharmaceuticals aims to expand market presence and provide a wider range of ophthalmic solutions. Under this agreement, NovaBay will market Eyenovia's Clobetasol propionate ophthalmic suspension, while Eyenovia will promote NovaBay's Avenova Antimicrobial Lid and Lash Solution. This collaboration intends to effectively target eye care professionals across the United States. However, the impact and success of this agreement remain to be seen.

Avenue Therapeutics Inc

Among many companies, the ATXI reported as well its fourth quarter of 2023 performance

Avenue Therapeutics Inc, a prominent pharmaceutical company, has been making waves in the medical industry with its groundbreaking advancements in the treatment of various neurological disorders. Recently, the company presented its preclinical data on BAER-101 at the American Society for Experimental Neurotherapeutics Annual Meeting, showcasing its full suppression of seizure activity in absence epilepsy. This discovery has the potential to revolutionize anti-seizure drug development and significantly improve the lives of those affected by this condition.
Absence epilepsy is a neurological disorder characterized by intermittent episodes of unconsciousness and staring spells. It predominantly affects children and adolescents, often leading to academic and social challenges. The underlying cause of this condition involves abnormal electrical activity in the brain, resulting in seizures characterized by momentary lapses in consciousness. Prompt and effective treatment is crucial in preventing long-term complications and enhancing the quality of life for individuals with absence epilepsy.

Leap Therapeutics Inc

Leap Therapeutics Inc Posts Operating Deficit of $14.82 Million in Latest Financial Report

Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million.
Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.

Xbiotech Inc

XBITsn Holds Steady Revenue in Fourth Quarter of 2023

Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects.
One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.






 

Myovant Sciences Ltd's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com